StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform
November 9, 2015 9:36 AM
Leerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Next Articles
AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients
November 9, 2015 8:02 AM
Relypsa (RLYP) Could Be Next High-Profile Takeout, Says Citi
November 6, 2015 10:09 AM
Notable Mergers and Acquisitions 11/6: (BABA)/(YOKU) (AZN)/(ZSPH) (FNGN) (DIOD)/(PSEM) (NSR)
November 6, 2015 10:02 AM
Pre-Open Stock Movers 11/06: (ZSPH) (LXRX) (WTW) Higher; (ICON) (MW) (KBIO) Lower (more...)
November 6, 2015 9:28 AM
Wall St. flat as rate hike eyed; banks counter utilities drop
November 6, 2015 7:28 AM
Relypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal
November 6, 2015 6:53 AM
AstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM
AstraZeneca buys ZS Pharma for $2.7 billion, pips Actelion
November 6, 2015 2:19 AM
After big spending and hard lobbying, Pfizer eyes new tax home
November 6, 2015 1:17 AM
Market Wrap: Valeant Investors Hit the Exits ... Again; Cabela's Draws Interest; United Airlines Chief to Return
November 5, 2015 5:56 PM
AstraZeneca (AZN) Tops Q3 EPS by 26c; Boosts FY15 EPS Growth Outlook
November 5, 2015 8:25 AM
